Investing.com -- 临床阶段精准肿瘤学公司Repare Therapeutics Inc (NASDAQ:RPTX)股价飙升15%,此前该公司宣布与Debiopharm达成其PKMYT1抑制剂lunresertib的全球独家许可协议。 根据协议条款,Repare将获得1000万美元的预付款,并有资格获得高达2.57亿美元的潜在里程碑付款,其中包括高达500万美元的近期付款。该公司还将...
Source LinkInvesting.com -- 临床阶段精准肿瘤学公司Repare Therapeutics Inc (NASDAQ:RPTX)股价飙升15%,此前该公司宣布与Debiopharm达成其PKMYT1抑制剂lunresertib的全球独家许可协议。 根据协议条款,Repare将获得1000万美元的预付款,并有资格获得高达2.57亿美元的潜在里程碑付款,其中包括高达500万美元的近期付款。该公司还将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.